|
1
|
Celik S, Oktenli C, Terekeci HM, et al:
Blood oxidative stress biomarkers in patients with familial
Mediterranean fever. Akt Rheumatol. 35:382–385. 2010.
|
|
2
|
Terekeci HM, Oktenli C, Ozgurtas T, et al:
Increased asymmetric dimethylarginine levels in young men with
familial Mediterranean fever (FMF): is it early evidence of
interaction between inflammation and endothelial dysfunction in
FMF? J Rheum. 35:2024–2029. 2008.
|
|
3
|
Terekeci HM, Ulusoy ER, Kucukarslan NM,
Nalbant S and Oktenli C: Familial Mediterranean fever attacks do
not alter functional and morphologic tissue Doppler
echocardiographic parameters. Rheum Int. 28:1239–1243. 2008.
|
|
4
|
Musabak U, Sengul A, Oktenli C, et al:
Does immune activation continue during an attack-free period in
familial Mediterranean fever? Clin Exp Immunol. 138:526–533.
2004.
|
|
5
|
Chae JJ, Cho YH, Lee GS, et al:
Gain-of-function Pyrin mutations induce NLRP3 protein-independent
interleukin-1β activation and severe autoinflammation in mice.
Immunity. 34:755–768. 2011.
|
|
6
|
Koc B, Oktenli C, Bulucu F, et al: The
rate of pyrin mutations in critically ill patients with systemic
inflammatory response syndrome and sepsis: a pilot study. J
Rheumatol. 34:2070–2075. 2007.
|
|
7
|
Centola M, Aksentijevich I and Kastner DL:
The hereditary periodic fever syndromes: molecular analysis of a
new family of inflammatory diseases. Hum Mol Genet. 7:1581–1588.
1998.
|
|
8
|
Diaz A, Hu C, Kastner DL, et al:
Lipopolysaccharide-induced expression of multiple alternatively
spliced MEFV transcripts in human synovial fibroblasts: a prominent
splice isoform lacks the C-terminal domain that is highly mutated
in familial Mediterranean fever. Arthritis Rheum. 50:3679–3689.
2004.
|
|
9
|
French FMF Consortium. A candidate gene
for familial Mediterranean fever. Nat Genet. 17:25–31. 1997.
|
|
10
|
The International FMF Consortium. Ancient
missense mutations in a new member of the RoRet gene family are
likely to cause familial Mediterranean fever. Cell. 90:797–807.
1997.
|
|
11
|
Touitou I: The spectrum of Familial
Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 9:473–483.
2001.
|
|
12
|
Bertin J and DiStefano PS: The PYRIN
domain: a novel motif found in apoptosis and inflammation proteins.
Cell Death Differ. 7:1273–1274. 2000.
|
|
13
|
Martinon F, Hofmann K and Tschopp J: The
pyrin domain: a possible member of the death domain fold family
implicated in apoptosis and inflammation. Curr Biol. 11:R118–R120.
2001.
|
|
14
|
Schaner P, Richards N, Wadhwa A, et al:
Episodic evolution of pyrin in primates: human mutations
recapitulate ancestral amino acid states. Nat Genet. 27:318–321.
2001.
|
|
15
|
Srinivasula SM, Poyet JL, Razmara M, et
al: The PYRIN-CARD protein ASC is an activating adaptor for
caspase-1. J Biol Chem. 277:21119–21122. 2002.
|
|
16
|
Chae JJ, Wood G, Richard K, et al: The
familial Mediterranean fever protein, pyrin, is cleaved by
caspase-1 and activates NF-kappaB through its N-terminal fragment.
Blood. 112:1794–1803. 2008.
|
|
17
|
Fernandes-Alnemri T, Wu J, Yu JW, et al:
The pyroptosome: a supramolecular assembly of ASC dimers mediating
inflammatory cell death via caspase-1 activation. Cell Death
Differ. 14:1590–1604. 2007.
|
|
18
|
Manji GA, Wang L, Geddes BJ, et al:
PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with
ASC and regulates activation of NF-kappa B. J Biol Chem.
277:11570–11575. 2002.
|
|
19
|
Matsushita K, Takeoka M, Sagara J, et al:
A splice variant of ASC regulates IL-1beta release and aggregates
differently from intact ASC. Mediators Inflamm.
2009:2873872009.
|
|
20
|
Stehlik C, Fiorentino L, Dorfleutner A, et
al: The PAAD/PYRIN-family protein ASC is a dual regulator of a
conserved step in nuclear factor kappaB activation pathways. J Exp
Med. 196:1605–1615. 2002.
|
|
21
|
Papin S, Cuenin S, Agostini L, et al: The
SPRY domain of Pyrin, mutated in familial Mediterranean fever
patients, interacts with inflammasome components and inhibits
proIL-1beta processing. Cell Death Differ. 14:1457–1466. 2007.
|
|
22
|
Stojanov S and Kastner DL: Familial
autoinflammatory diseases: genetics, pathogenesis and treatment.
Curr Opin Rheumatol. 17:586–599. 2005.
|
|
23
|
Hallek M, Bergsagel PL and Anderson KC:
Multiple myeloma: increasing evidence for a multistep
transformation process. Blood. 91:3–21. 1998.
|
|
24
|
Li ZW, Chen H, Campbella RA, Bonavidab B
and Berensona JR: NF-kappaB in the pathogenesis and treatment of
multiple myeloma. Curr Opin Hematol. 15:391–399. 2008.
|
|
25
|
Annunziata CM, Davis RE, Demchenko Y, et
al: Frequent engagement of the classical and alternative NF-kappaB
pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell. 12:115–130. 2007.
|
|
26
|
Keats JJ, Fonseca R, Chesi M, et al:
Promiscuous mutations activate the noncanonical NF-kappaB pathway
in multiple myeloma. Cancer Cell. 12:131–144. 2007.
|
|
27
|
Oktenli C, Sayan O, Celik S, et al: High
frequency of MEFV gene mutations in patients with myeloid neoplasm.
Int J Hematol. 91:758–761. 2010.
|
|
28
|
Celik S, Erikci AA, Tunca Y, et al: The
rate of MEFV gene mutations in hematolymphoid neoplasms. Int J
Immunogenet. 37:387–391. 2010.
|
|
29
|
Sayan O, Kilicaslan E, Celik S, et al:
High frequency of inherited variants in the MEFV gene in acute
lymphocytic leukemia. Indian J Hematol Blood Transfus. 27:164–168.
2011.
|
|
30
|
Celik S, Oktenli C, Kilicaslan E, et al:
Frequency of inherited variants in the MEFV gene in myelodysplastic
syndrome and acute myeloid leukemia. Int J Hematol. 95:285–290.
2012.
|
|
31
|
Oktenli C and Celik S: High frequency of
inherited variants in the MEFV gene in patients with hematologic
neoplasms: a genetic susceptibility? Int J Hematol. 95:380–385.
2012.
|
|
32
|
Vangsted AJ, Nielsen KR, Klausen TW, et
al: A functional polymorphism in the promoter region of the IL-1B
gene is associated with risk of multiple myeloma. Br J Haematol.
158:515–518. 2012.
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.
|
|
34
|
Bottero V, Withoff S and Verma IM:
NF-kappaB and the regulation of hematopoiesis. Cell Death Differ.
13:785–797. 2006.
|
|
35
|
Grossmann M, Metcalf D, Merryfull J, et
al: The combined absence of the transcription factors Rel and RelA
leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA.
96:11848–11853. 1999.
|
|
36
|
Siebenlist U, Brown K and Claudio E:
Control of lymphocyte development by nuclear factor-kappaB. Nat Rev
Immunol. 5:435–445. 2005.
|
|
37
|
Karin M and Greten FR: NF-kappaB: linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005.
|
|
38
|
Keutgens A, Robert I, Viatour P and
Chariot A: Deregulated NF-kappaB activity in haematological
malignancies. Biochem Pharmacol. 72:1069–1080. 2006.
|
|
39
|
Stoffel A: The NF-kappaB signalling
pathway: a therapeutic target in lymphoid malignancies? Expert Opin
Ther Targets. 9:1045–1061. 2005.
|
|
40
|
Salem K, Brown CO, Schibler J and Goel A:
Combination chemotherapy increases cytotoxicity of multiple myeloma
cells by modification of nuclear factor (NF)-κB activity. Exp
Hematol. 41:209–218. 2013.
|
|
41
|
Ni H, Ergin M, Huang Q, et al: Analysis of
expression of nuclear factor kappa B (NF-kappa B) in multiple
myeloma: downregulation of NF-kappa B induces apoptosis. Br J
Haematol. 115:279–286. 2001.
|
|
42
|
Bharti AC, Donato N, Singh S and Aggarwal
BB: Curcumin (diferuloylmethane), down-regulates the constitutive
activation of nuclear factor-kappa B and IkappaBalpha kinase in
human multiple myeloma cells, leading to suppression of
proliferation and induction of apoptosis. Blood. 101:1053–1062.
2003.
|
